New drug combo shows promise for untreated CLL patients
NCT ID NCT03447808
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 22 times
Summary
This early-phase study tested a combination of two drugs, daratumumab and ibrutinib, in 15 people with untreated chronic lymphocytic leukemia (CLL) who needed treatment. The goal was to see how safe the combination is and how well it works at controlling the disease. Participants received both drugs, and researchers tracked side effects and cancer response. While the treatment aims to control CLL, it is not a cure, and ongoing management may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.